INCY
Incyte Corporation Healthcare - Biotechnology Investor Relations →
Incyte Corporation (INCY) closed at $90.78 as of 2026-03-20, trading 26.6% above its 200-week moving average of $71.69. The stock is currently moving closer to the line, down from 29.2% last week. The 14-week RSI sits at 45, indicating neutral momentum.
Trading volume is running at 1.6x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.12 ratio) is neutral — neither side is clearly dominating.
Over the past 1641 weeks of data, INCY has crossed below its 200-week moving average 24 times. On average, these episodes lasted 31 weeks. Historically, investors who bought INCY at the start of these episodes saw an average one-year return of +70.0%.
With a market cap of $18.1 billion, INCY is a large-cap stock. The company generates a free cash flow yield of 3.4%. Return on equity stands at 29.9%, indicating strong profitability. The stock trades at 3.5x book value.
The company has been aggressively buying back shares, reducing its share count by 10.9% over the past three years. INCY passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow.
Over the past 31.5 years, a hypothetical investment of $100 in INCY would have grown to $4762, compared to $2377 for the S&P 500. That represents an annualized return of 13.0% vs 10.6% for the index — confirming INCY as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: INCY vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After INCY Crosses Below the Line?
Across 24 historical episodes, buying INCY when it crossed below its 200-week moving average produced an average return of +46.1% after 12 months (median -1.0%), compared to +11.2% for the S&P 500 over the same periods. 46% of those episodes were profitable after one year. After 24 months, the average return was +32.7% vs +13.9% for the index.
Each line shows $100 invested at the moment INCY crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
INCY has crossed below its 200-week MA 24 times with an average 1-year return of +70.0% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Oct 1994 | Nov 1994 | 4 | 20.1% | +192.1% | +4511.0% |
| Aug 1998 | Oct 1998 | 8 | 17.2% | +26.9% | +807.8% |
| Mar 1999 | Jun 1999 | 17 | 33.3% | +879.1% | +622.6% |
| Jul 1999 | Aug 1999 | 6 | 10.1% | +271.0% | +591.7% |
| Sep 1999 | Nov 1999 | 10 | 38.5% | +246.2% | +680.9% |
| Dec 2000 | Jan 2001 | 3 | 14.3% | -11.6% | +278.2% |
| Jan 2001 | Oct 2004 | 194 | 87.8% | -35.5% | +291.5% |
| Nov 2004 | Nov 2004 | 1 | 1.6% | -46.9% | +846.6% |
| Jan 2005 | Jul 2005 | 26 | 23.0% | -39.4% | +896.5% |
| Aug 2005 | Sep 2005 | 5 | 7.5% | -42.3% | +1100.8% |
| Sep 2005 | Jan 2007 | 68 | 39.1% | -41.9% | +1152.1% |
| Feb 2007 | Mar 2007 | 3 | 7.2% | +64.3% | +1405.5% |
| Jun 2007 | Sep 2007 | 14 | 28.3% | +36.9% | +1364.2% |
| Sep 2008 | Aug 2009 | 46 | 67.6% | -0.7% | +1257.0% |
| Oct 2009 | Nov 2009 | 2 | 9.3% | +200.9% | +1512.4% |
| Jan 2018 | Nov 2019 | 95 | 38.9% | -3.5% | +5.7% |
| Dec 2019 | Apr 2020 | 17 | 26.2% | -2.0% | +0.8% |
| Aug 2020 | Jan 2021 | 18 | 10.1% | -15.9% | +0.3% |
| Feb 2021 | Mar 2022 | 59 | 19.8% | -20.8% | +7.6% |
| Apr 2022 | Nov 2022 | 32 | 17.5% | -2.6% | +18.5% |
| Dec 2022 | Jan 2023 | 3 | 0.7% | -21.8% | +13.0% |
| Feb 2023 | Oct 2024 | 90 | 32.5% | -27.3% | +14.5% |
| Dec 2024 | Jan 2025 | 4 | 1.9% | +39.2% | +32.4% |
| Mar 2025 | Jun 2025 | 14 | 17.3% | +36.4% | +33.8% |
| Average | 31 | — | +70.0% | — |
Frequently Asked Questions
Is INCY below its 200-week moving average?
No. Incyte Corporation (INCY) is currently 26.6% above its 200-week moving average of $71.69. It would need to fall to $71.69 to cross below the line.
What is INCY's 200-week moving average price?
Incyte Corporation's 200-week moving average is $71.69 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when INCY drops below its 200-week moving average?
INCY has crossed below its 200-week moving average 24 times in our data. On average, buying at that moment produced a one-year return of +70.0%. These dips have historically been decent entry points. These episodes lasted 31 weeks on average.
Is INCY a good value right now?
Here's what our data says about INCY as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 45. Free cash flow yield is 3.4%. Return on equity is 29.9%. Price-to-book is 3.5x. This is not a buy or sell recommendation — always do your own research.
How does INCY compare to the S&P 500?
Over the past 31.5 years, $100 invested in INCY would have grown to $4762, compared to $2377 for the S&P 500. That's 13.0% annualized vs 10.6% for the index. INCY has outperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20